GOLDMAN SACHS GROUP INC - 31 Dec 2025 SCHEDULE 13G/A Report for 4D MOLECULAR THERAPEUTICS, INC. Common Stock, par value $0.0001 per share (FDMT)

Filing Manager
GOLDMAN SACHS GROUP INC
Reporting Manager
THE GOLDMAN SACHS GROUP, INC.
Security
4D MOLECULAR THERAPEUTICS, INC. Common Stock, par value $0.0001 per share
Symbol
FDMT
Shares outstanding
57,147,700 shares
Disclosed Ownership
4,286,077 shares
Ownership
7.5%
Form type
SCHEDULE 13G/A
Filing time
09 Feb 2026, 16:05:49 UTC
Date of event
31 Dec 2025
Previous filing
10 Feb 2025
SEC
View on sec.gov

Quoteable Key Fact

"GOLDMAN SACHS GROUP INC disclosed 7.5% ownership in 4D MOLECULAR THERAPEUTICS, INC. Common Stock, par value $0.0001 per share (FDMT) on 31 Dec 2025."

Quick Takeaways

  • GOLDMAN SACHS GROUP INC filed SCHEDULE 13G/A for 4D MOLECULAR THERAPEUTICS, INC. Common Stock, par value $0.0001 per share (FDMT).
  • Disclosed ownership: 7.5%.
  • Date of event: 31 Dec 2025.

What Changed

  • Previous schedule filing date: 10 Feb 2025.
  • Current filing was accepted on 09 Feb 2026, 16:05.

Why This Matters

  • This page explains what this Schedule 13D/13G filing tells you before manager-level rows.
  • You can verify ownership claims directly against the original SEC filing.

Source Evidence

Backed by Schedule 13D/13G

Beneficial ownership values are sourced from the original SEC Schedule 13D/13G filing.

See Original Filing

Reporting Managers (2)

Name Ownership Shares Owned sole voting power shared voting power Signature Title CIK
THE GOLDMAN SACHS GROUP, INC. 7.5% 4,286,077 0 4,286,060 Name: Sam Prashanth Attorney-in-fact
GOLDMAN SACHS & CO. LLC 7.5% 4,286,077 0 4,286,060 Name: Sam Prashanth Attorney-in-fact